BioPharmSignal logoBioPharmSignal

Biotech News

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Science (GNTA)Genenta SciencePartnership

MILAN , Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”)

Related news

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

NRIXNurix Therapeutics2026-06-08 05:00 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

View all latest news

Genenta Science

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

Recent company news

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

GNTAGenenta Science2026-04-23 11:00 EST

Genenta signs Definitive Agreements with Sophia High Tech

GNTAGenenta Science2026-03-27 09:00 EST

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

GNTAGenenta Science2026-03-24 07:26 EST

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Stock data

Close
1.26 USD
Market cap
51.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States